Skip to Content
Søk Menu

ASH | American Society of Hematology Meeting & Exposition

ASH 2025

Alma Månsson

Opposing Roles of LAMA4 in the Bone Marrow Niche During CML

/ Alma Månsson
ASH25CMLLeukemi Play the Video

Myelomatose er et svært dynamisk behandlingsfelt

/ Fredrik Schjesvold / Jan Andreasen
ASH25Myelomatose

MRDas an Early Indicator of SurvivalCould Fast-Track Conditional Approval for New Treatments of AML

/ Jan Andreasen
AMLASH25

New Opportunities to Improve Care for People Living with Sickle Cell Disease

/ Jan Andreasen
ASH25
Johan Gustafsson

Towards Identifying Which CLL Patients with Richter Transformation Respond to Immune Checkpoint Inhibitor Therapy

/ Johan Gustafsson
ASH25 Play the Video

Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment

/ Frida Bugge Askeland / Jan Andreasen
ASH25Myelomatose

Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS

/ Jan Andreasen
ASH25
Signe Modvig

Danish Research Identifies Promising New Target for Preventing CNS Relapse in ALL

/ Signe Modvig
ASH25 Play the Video

BPd Preserved or Improved Quality of Life in Patients with RRMM

/ Paul G. Richardson / Jan Andreasen
ASH25Myelomatose
Ingrid Cecilia Glimelius

Novel Clinical Data in Mantle Cell Lymphoma Highlighted in ASH 2025 Oral Session

/ andreasstoevhase
ASH25 Play the Video
Ingrid Cecilia Glimelius

Nordic Study Uncovers a New Minimally Invasive Biomarker for Low-Risk Mantle Cell Lymphoma

/ Ingrid Cecilia Glimelius
ASH25 Play the Video
Henrik Hjorth-Hansen

Improving CML Outcomes: Nordic CML Study Group Shares New ASH 2025 Insights

/ Henrik Hjorth-Hansen
ASH25Lymfom Play the Video
Wojciech Jurczak

Pirtobrutinib Showed Positive Efficacy and Safety vs Ibrutinib in BTKi-naïve CLL/SLL Patients Both for Treatment-naïve Patients and Patients with R/R Disease

/ Wojciech Jurczak
ASH25CLL Play the Video
Waleed Ghanima

Norwegian Study Can Change the Clinical Practice for Patients with Immune Thrombocytopenia

/ Waleed Ghanima
ASH25 Play the Video
Jelena Jelicic

Danish Study Finds That Variability in Eligibility Criteria Hampers Comparability of Frontline DLBCL Trials

/ Jelena Jelicic
ASH25Lymfom Play the Video
Astrid Hundeboell Torpe

ASH 2025: Prophylactic Tocilizumab Reduces CRS

/ Astrid Hundebøll Torpe
ASH25Multiple myeloma Play the Video

Top Abstract Spotlight: Menin Inhibitors are a Game Changer for the Treatment of Patients with Newly Diagnosed AML 

/ Jan Andreasen
AMLASH25
Load more

ASH 2025 Highlights – Nordic Webinar 

Stay up to date with the most relevant findings and developments presented at ASH 2025. Nordic experts will highlight key clinical data, emerging treatment strategies, and their potential impact on patient care. Join the live session or watch it on demand at your convenience.

ASH 2024

Advancing Towards New Treatment Options for AML

  • / Jan Andreasen

Hematology • Meet the experts

Få tilgang

Even Though There Was Little Game-Changing Data, ASH 2024 Provided a Valuable Overview of the Future of Hematology Treatment Across Our Diseases

/ Hematologi / Jan Andreasen

Key Findings That Could Transform Multiple Myeloma Treatment

/ Hematologi / Jan Andreasen

CLL: Encouraging Results and The Balance Between Deep Response and Side Effects

/ Hematologi / Jan Andreasen

Ingen ændringer i behandlingen inden for lymfom efter ASH 2024, men mange vigtige updates

/ Hematologi / Tarec Christoffer El-Galaly

ASH 2024: Nyt om AML i dansk perspektiv

/ Hematologi / Hans Beier Ommen
Emelie Hamotal Curovic Rotbain

Dansk Aften ASH 2024: Nye fremskridt i behandling af CLL

/ Emelie Hamotal Curovic Rotbain
ASH24CLL Play the Video
Betty Gardie & François Girdon

LBA-2: A New Cause of Hereditary and Acquired Erythrocytosis

/ Betty Gardie / Francois Girodon
ASH24 Play the Video
Bjørn Tore Gjertsen

ASH 2024: AML-forskning tar nye steg med CPX-behandling og meninhemmere

/ Bjørn Tore Gjertsen
AMLASH24 Play the Video
Tobias Schmidt Slørdahl

ASH 2024: Siste behandlinger og forskningsfremskritt innen hematologi

/ Tobias S. Slørdahl
ASH24 Play the Video
Fredrik Hellem Schjesvold

ASH 2024: Viktige funn som kan endre behandlingen av myelomatose

/ Fredrik Schjesvold
ASH24Myelomatose Play the Video
Fabian Müller

Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression

/ Fabian Mueller
ASH24CAR-T Play the Video
Alexander Fuglkjær

Machine Learning Can Reduce Unnecessary Hospitalizations for Cancer Patients

/ Alexander Fuglkjær
AIASH24Lymfom Play the Video
Muhammad Kashif

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Muhammad Kashif
AIASH24Myelomatose Play the Video
Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video
Load more

ASH 2023

Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video
Jason Westin

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Jason Westin
ASH23B-celle lymfom Play the Video
Eva Birgitte Leinøe

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Eva Birgitte Leinøe
ASH23 Play the Video
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelomatose Play the Video

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ BestPractice Nordic
ASH23CLL
Load more

ASH 2022

Christine Ryan

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Christine Ryan
ASH22CLL Play the Video
Ryan Jacobs

CLL - The impact of using ibrutinib as front-line treatment

/ Ryan Jacobs
ASH22CLL Play the Video
Eunice Wang

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Eunice Wang
AMLASH22 Play the Video
Roch Houot

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Roch Houot
ASH22Lymfom Play the Video
Régis Peffault De Latour

Superior efficacy of Iptacopan in PNH patients

/ Régis Peffault De Latour
ASH22 Play the Video
Carsten Utoft Niemann

CLL – Update from ASH 2022

/ Carsten Utoft Niemann
ASH22CLL Play the Video
Load more

ASH 2021

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Paul G. Richardson
ASH21Myelomatose Play the Video

Update om behandling af myelomatose med bispecifikke antitoffer

/ Agoston Gyula Szabos
ASH21Myelomatose Play the Video
Andrew H. Wei

Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival

/ Andrew Wei
AMLASH21 Play the Video
Alexander Fosså

CAR-T-terapi til behandling av storcellet B-cellelymfom

/ Alexander Fosså
ASH21Lymfom Play the Video
Evangelos Terpos

Safe to use Belantamab Mafodotin for transplant-ineligible patients with newly diagnosed multiple myeloma

/ Evangelos Terpos
ASH21Myelomatose Play the Video
Bjørn Tore Gjertsen

Relapse vaccine is a promising treatment for patients with AML

/ Bjørn Tore Gjertsen
AMLASH21 Play the Video
Manali Kamdar

CAR T Cell Therapy - a new standard of care for 2L treatment of R/R in Large B-cell Lymfoma

/ Manali Kamdar
ASH21Lymfom Play the Video
Matthew S. Davids

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Matthew S. Davids
ASH21KLL Play the Video
Load more
Back to top